Should you buy CSL shares before it's too late?

The CSL share price is currently trading 16% below its all-time high. Is now the time to buy shares in the biotech giant before it's too late?

| More on:
CSL share price Digitised bubbles of cells representing ASX biotech shares such as CSL

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL share price is currently trading 16.7% below its all-time high of $342.75. As we have seen recently, many quality shares that have been sold-off can surge in an unstoppable rally on the turn of a dime.

With the CSL share price consolidating, is now the time to buy shares in the biotech giant before its too late?

Why is the CSL share price not at all-time highs?

The fact that CSL is trading below its all-time highs could reflect portfolio rotation among many investors. With the broader market performing stronger than expected, many investors will be opting to take their profits and sell blue-chips like CSL. By freeing up capital, investors can then load their portfolio with more beaten-down laggards and other cyclical shares.

In addition to portfolio rotation, some investors might be selling their CSL shares as the company faces rising collection costs during the coronavirus pandemic.

How has CSL performed during the pandemic?

Although CSL is not actively participating in the race to develop a vaccine for COVID-19, the biotech giant is working to develop potential therapies by collecting plasma from recovered patients. In conjunction with other global biotech companies, CSL has launched a campaign in the US encouraging recovered COVID-19 patients to donate plasma. CSL is also collecting recovered donor plasma in Australia, with the company partnering with the Australian Red Cross Lifeblood Service.

There have been some concerns that the global shutdowns as a result of the pandemic may result in a supply shortage in plasma collection. In addition, CSL has the obligation to ensure the safety of its donors by undertaking various disinfecting and screening protocols, which could impact margins.  

Bullish broker note

Earlier this month, analysts from broker UBS released a bullish note on CSL and slapped a $342 12-month price target on the company. Analysts flagged a 15% decline in plasma collection volume for the April–June period, however volumes are expected to recover as US states move to ease regulations. Researchers from the broker continue to see CSL as the preferred option in the health sector based on the company's robust product pipeline and low level of gearing.

Should you buy?

In my experience, the fear of missing out, especially in unprecedented times such as this, can cloud the decision making of the most experienced investor. However, in the case of a quality company such as CSL, the decision should be straightforward. This market darling has a strong capital position with more than $1 billion in available liquidity and has also reaffirmed its profit guidance for FY20.

If portfolio rotation is the cause for a drop in CSL's share price, I think that it won't be sustained for too long and buyers should flood in again. For more cautious investors it may be prudent to wait until August when CSL reports its full-year results to get a better picture of where the company stands.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 9 January 2025

Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing start to the week for ASX investors this Tuesday.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
52-Week Highs

7 ASX 200 stocks hitting multi-year highs today

These stocks have hit new price milestones amid a volatile day for the ASX 200.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

Where's the ASX 200 heading in 2025? Here's what the experts say

We canvas the views of several experts.

Read more »

A young woman makes an online travel booking as she sits on some steps with her suitcase next to her.
Opinions

Is it time to buy these 2 beaten-up ASX shares in 2025?

These stocks are compelling buys, in my view.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Brokers just upgraded these 3 ASX stocks to buys

It's bullish ratings galore for investors this week.

Read more »

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Share Fallers

Why Bellevue Gold, Brainchip, Deep Yellow, and Goodman shares are sinking today

These shares are starting the week deep in the red. What's going on?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Dropsuite, Monadelphous, Sigma, and Telix shares are storming higher today

These shares are starting the week on a positive note. But why?

Read more »